No Data
Ascendis Pharma Announces 2-Year Results From A Post-hoc Analysis Of Their Phase 3 Pathway Trial Demonstrating Sustained Improvements In Renal Function In Adults With Chronic Hypoparathyroidism Treated With TransCon PTH
Ascendis Pharma A/S (NASDAQ:ASND) today announced 2-year results from a post-hoc analysis of the Company's Phase 3 PaTHway Trial demonstrating significant and sustained improvements in renal function
Ascendis Pharma A/S Clinical And Quality-Of-Life Data For TransCon PTH-Treated Adults With Chronic Hypoparathyroidism To Be Presented At ECE 2024
Ascendis Pharma A/S (NASDAQ:ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefits in adult patients with chronic hypoparathyroidism wi
$100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 15 years by 16.63% on an annualized basis producing an average annual return of 28.88%. Currently, Ascendis Pharma has a market
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
European equities traded in the US as American depositary receipts started the week off on a positive note, rising 0.42% to 1,380.39 on the S&P Europe Select ADR Index. From continental Europe, the ga
Ascendis Pharma Price Target Raised to $170.00/Share From $167.00 by JP Morgan
Ascendis Pharma Price Target Raised to $170.00/Share From $167.00 by JP Morgan
Ascendis Pharma Is Maintained at Overweight by JP Morgan
Ascendis Pharma Is Maintained at Overweight by JP Morgan
baqklin : thanks
74349332 : what site do you get this informatiom from?